In long-term ALS survival, the second most important device after invasive ventilation is probably the cough assist machine. In practice, the two are tightly linked. The real advantage of invasive ventilation over noninvasive ventilation is not merely more stable breathing support. It is that airway clearance becomes far more effective.
A ventilator can move air in and out. But if secretions accumulate and cannot be cleared, the patient still dies - usually from pneumonia, mucus plugging, or gradual collapse of lung function. Respiratory failure in ALS is often presented as a problem of weak breathing muscles alone. In reality, a weak cough is just as dangerous.
The normal cough reflex is an extraordinarily powerful mechanism. It generates very high expiratory flow rates that clear mucus, saliva, food particles, bacteria, and inflammatory debris from the airways. ALS progressively destroys this capability. Once cough strength falls below a critical threshold, secretions begin to remain in the lungs. Infection risk rises sharply. Oxygenation worsens. Each infection leaves the lungs weaker than before.
This is where cough assist becomes essential. The machine rapidly alternates positive and negative pressure, simulating a natural cough with far greater effectiveness than ordinary suctioning. Used properly and early enough, it can clear deep secretions that would otherwise remain trapped. In many cases, it is the difference between staying at home and ending up intubated in intensive care.
Yet the healthcare system often treats cough assist almost as an afterthought. Ventilation gets discussed. Oxygen saturation is monitored. But airway clearance receives surprisingly little emphasis. Some patients are never introduced to cough assist. Others are denied access because they do not fit rigid criteria. Sometimes the machine is available, but training is inadequate, and usage remains too timid to be effective.
The consequence is predictable. Patients die from pneumonia that could likely have been prevented.
Once invasive ventilation is established, cough assist often becomes more effective because the tracheostomy provides a direct airway. The pressures transmit better. Secretion clearance becomes more reliable. For many long-term survivors, aggressive airway clearance is as important as the ventilator itself.
The system tends to frame ALS as an inevitably fatal neurodegenerative disease. But many deaths attributed to ALS are, in practice, deaths from poor secretion management. There is a difference.
Motor neurons may not recover. But mucus can still be removed.
***
ALS often becomes a respiratory disease long before it becomes a purely oxygenation problem. The danger is not only weak breathing, but also weak coughing. Mucus stays in the lungs, small airways collapse, infections accumulate, and eventually the patient enters a cycle of repeated pneumonias, hospitalizations, and progressive loss of lung function.
Many people focus on tracheal suctioning as the answer. But suctioning mainly removes secretions that are already in the central airway. It does little to address the deeper problem: mucus trapped deep in poorly ventilated lung regions, where the patient no longer has the muscle strength to generate an effective cough.
A better strategy may be preserving the ability to clear the lungs without invasive airway trauma. That is where cough assist devices become critical.
A mechanical insufflation-exsufflation device effectively replaces the missing cough reflex. It pushes air into the lungs and then rapidly reverses flow outward, creating the high expiratory flow needed to mobilize secretions from deep airways toward the throat. Instead of repeatedly inserting suction catheters into an increasingly fragile airway, the lungs are cleared more physiologically by airflow.
Trendelenburg positioning adds another overlooked advantage.
By placing the body with the head lower than the chest, gravity begins to help move secretions from lower lung regions toward the central airways, where cough assist can remove them more effectively. In patients with weakened lungs, gravity may become part of the respiratory support system.
Combining the two has several advantages:
- less airway trauma than repeated tracheal suctioning
- better mobilization of secretions from deep lung regions
- reduced risk of mucus plugging and atelectasis
- fewer infections caused by retained secretions
- better preservation of lung compliance over time
Repeated suctioning can become a vicious cycle. The airway becomes irritated, secretions increase, coughing weakens further, and deeper mucus remains untouched. The intervention treats the symptom visible at the tube - not necessarily the mechanics of secretion transport throughout the lungs.
It also carries an infection risk if high hygiene standards are not followed.
Long-term survival in ALS may depend less on “removing mucus from the trachea” and more on preserving an entire secretion-clearing system despite failing muscles.
The body originally evolved to clear the lungs using airflow, pressure changes, posture, and cough mechanics together. Cough assist and positioning attempt to restore that system artificially after the muscles can no longer do it alone.
One of the strangest realities in ALS care is that the most important life-prolonging device - the cough-assist machine - is still met with hesitation in many places.
The reasoning is not entirely irrational. Mechanical insufflation-exsufflation is not completely risk-free. Aggressive pressure swings can occasionally irritate the airways, cause small lung injuries, or, in rare cases, contribute to pneumothorax. More commonly, treatment may loosen large mucus plugs that the patient cannot adequately clear without proper suction and monitoring.
For physicians trained primarily to avoid immediate procedural complications, this creates discomfort. A patient may appear relatively stable while quietly accumulating secretions over weeks or months. The danger remains mostly invisible. Then, cough assist is initiated, secretions mobilize dramatically, and suddenly the situation becomes acute and highly visible.
The irony is that this often means the device is blamed for revealing the problem rather than for causing it.
Without cough assist, the same patient may simply progress toward pneumonia, chronic hypoxia, atelectasis, respiratory exhaustion, and eventual death in a slower and less conspicuous manner. That trajectory appears “natural.” The death certificate says ALS or pneumonia. Nobody feels directly responsible.
This creates a subtle but powerful bias throughout medicine. Slow deterioration caused by insufficient support is psychologically easier for the system to accept than a visible complication associated with active intervention.
One neurologist summarized this mentality with brutal honesty: “It is better that the patient dies of disease rather than treatment.”
From an institutional risk-management perspective, that statement is understandable. From the patient’s perspective, it is horrifying.
The problem is that ALS patients rarely die because motor neurons suddenly vanish overnight. They often die from secondary consequences:
- secretion retention
- ineffective cough
- recurrent infections
- exhaustion
- hypoventilation
- progressive collapse of airway
ough assist directly targets one of the disease’s central mechanical failures: the inability to generate sufficient expiratory flow to clear mucus.
Healthy people unconsciously constantly clear small secretions. ALS patients gradually lose that ability. Mucus then accumulates silently until infection, obstruction, or hypoxia develops.
At that stage, avoiding the cough assist because of theoretical risks starts to resemble refusal to use seatbelts, since bruises occasionally occur during accidents.
Of course, proper use is very important. Pressure settings must be individualized. Patients require supervision during adaptation. Suction capability should exist when necessary. Extremely fragile lungs deserve caution. But these are arguments for competent use, not for avoidance.
The deeper issue is that medicine often evaluates interventions asymmetrically.
The risks of active treatment are counted precisely and documented immediately.
The risks of undertreatment are diffuse, delayed, and easier to attribute to “disease progression.”
In ALS, this distinction can become deadly.
A patient slowly drowning in retained secretions may look medically inevitable. A patient experiencing temporary distress during aggressive secretion clearance looks like a treatment complication. Yet the first scenario may be far more dangerous in the long run.
From an energy perspective, the consequences are obvious. Retained mucus increases airway resistance, worsens oxygen transfer, increases infection risk, and forces exhausted respiratory muscles to work continuously harder. The nervous system spends enormous energy merely trying to maintain ventilation through partially obstructed lungs.
Cough assist does not cure ALS. But by preserving airway clearance, it may substantially reduce one of the major downstream mechanisms by which ALS patients actually die.